Shots:

• The company highlighted the 24wk. results from the P-III (BE OPTIMA) study & 16wk. from the P-III (BE COMPLETE) study evaluating bimekizumab vs PBO in adults with active PsA who were biologic naïve and TNFi-IR
• The trial met their 1EPs & 2EPs i.e., patients achieved a joint symptoms improvement @16wks. as measured by ACR50 & high levels of skin clearance as measured by PASI 90 with consistent clinical response in biologic-naïve & TNFi-IR populations. The safety profile was consistent with prior studies with no new observed safety signals 
• Bimekizumab has been approved in the EU/ EEA & Great Britain for sev. PsO in adults who are candidates for systemic therapy

Ref: PRNewswire | Image: UCB